UNSPSC 51401504: Cinolazepam

This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68P0556B0U, chemically known as 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1h-1,4-benzodiazepine-1-propionitrile but generally known as cinolazepam, which bears US NIH Compound Identifier 3033621. European Medicines Agency schedules Cinolazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06307MIG.

UNSPSC 51401504 Cinolazepam is a Commodity code under which state and local governments procure pharmaceutical and medical countermeasure products. The recent solicitation activity shows that the code encompasses naloxone and drug deactivation systems acquired for public health emergency response and community health initiatives, though the posted opportunity centers on these naloxone and deactivation products rather than cinolazepam specifically.

Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The county required electronic bid submission through its e-Procurement Portal, E-Verify compliance, drug-free workplace certification, and specified insurance coverage including workers' compensation and commercial general liability. The contract offered a two-year initial term with a one-year renewal option and included potential FEMA funding with associated federal compliance obligations. This represents the only recent state and local opportunity identified under this code; the geographic and issuing-body scope cannot be reliably characterized from a single opportunity.